Security key
603170101
Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MLYS)
CUSIP: 603170101
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 65,687,280
- Total 13F value
- $888,767,559
- Share change
- +4,565,614
- SEC-reported price per share
- $13.53
- Number of holders
- 164
- Value change
- +$52,640,107
- Number of buys
- 117
- Number of sells
- 53
- Shares outstanding
- 79,235,030
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
164
Top holders
10
MLYS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Mineralys Therapeutics, Inc. SEC filings
Mineralys Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 603170101
Recent filing periods:
Ownership snapshot
Top reported holders of MLYS - Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Andera Partners
Disclosed value leader
Catalys Pacific, LLC
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
Lead comparable stake: 4.2%
13D/G row: Andera Partners
Showing 1-6 of 15 holder rows.
Quick read
Andera Partners leads the comparable SEC ownership view at 4.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Andera Partners's linked filing trail.
Comparable ownership
Top 5
Andera Partners
4.2%
ADAMS STREET PARTNERS LLC
2.3%
Catalys Pacific, LLC
11%
RA CAPITAL MANAGEMENT, L.P.
7.8%
Samsara BioCapital, LLC
7.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Andera Partners |
13D/G
|
4.2%
|
$39,747,075
2,765,976 shares
|
$0 | 30 Jun 2025 |
| ADAMS STREET PARTNERS LLC |
13D/G
|
2.3%
|
$15,320,183
1,129,807 shares
|
$0 | 31 Dec 2024 |
| Catalys Pacific, LLC |
13F
Company
|
11%
|
$141,392,947
8,903,838 shares
|
— | 31 Mar 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
7.8%
|
$97,618,806
6,147,280 shares
|
— | 31 Mar 2025 |
| Samsara BioCapital, LLC |
13F
Company
|
7.2%
|
$90,117,666
5,674,916 shares
|
— | 31 Mar 2025 |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
Company
|
3.9%
|
$49,671,576
3,127,933 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
164
Shares
65,687,280
Rows available
164
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
148
Q2 2025 holders
164
Holder diff
16
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend